Brokers Set Expectations for Innoviva FY2025 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Innoviva in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will post earnings per share of $1.55 for the year. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The firm had revenue of $89.51 million during the quarter.

Separately, StockNews.com downgraded Innoviva from a “buy” rating to a “hold” rating in a research note on Tuesday, December 31st.

Innoviva Trading Down 1.2 %

NASDAQ:INVA opened at $18.53 on Wednesday. The business’s 50-day moving average is $18.34 and its two-hundred day moving average is $18.77. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.79 and a quick ratio of 1.64. Innoviva has a 12 month low of $14.32 and a 12 month high of $21.28. The firm has a market capitalization of $1.16 billion, a PE ratio of 26.86 and a beta of 0.54.

Hedge Funds Weigh In On Innoviva

A number of hedge funds have recently bought and sold shares of INVA. American Century Companies Inc. grew its stake in Innoviva by 369.6% in the second quarter. American Century Companies Inc. now owns 459,690 shares of the biotechnology company’s stock worth $7,539,000 after purchasing an additional 361,797 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Innoviva by 1.5% in the second quarter. Dimensional Fund Advisors LP now owns 4,684,594 shares of the biotechnology company’s stock worth $76,826,000 after purchasing an additional 71,336 shares in the last quarter. Mercer Global Advisors Inc. ADV grew its stake in Innoviva by 25.3% in the second quarter. Mercer Global Advisors Inc. ADV now owns 29,420 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 5,940 shares in the last quarter. Hsbc Holdings PLC grew its stake in Innoviva by 45.3% in the second quarter. Hsbc Holdings PLC now owns 57,832 shares of the biotechnology company’s stock worth $936,000 after purchasing an additional 18,026 shares in the last quarter. Finally, Intech Investment Management LLC acquired a new position in Innoviva in the second quarter worth about $249,000. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.